Regional-dependent intestinal permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 589-597

  Fairstein, Moran ^a   Swissa, Rotem ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

BCS classification; biowaiver; intestinal absorption; regioselective absorption; segmental dependent permeability

Indexed keywords

METOPROLOL; PSEUDOEPHEDRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT;

ADMINISTRATION, ORAL; ANIMALS; BUFFERS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; MEMBRANES, ARTIFICIAL; METOPROLOL; NASAL DECONGESTANTS; OCTANOLS; PERMEABILITY; PSEUDOEPHEDRINE; RATS; RATS, WISTAR; SOLUBILITY;

EID: 84877070455     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9462-x     Document Type: Article

References (44)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
2. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res. 1988;5(10):651-4. doi: 10.1023/a:1015927004752.
3. Dahan A, Miller J, Amidon G. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009;11(4):740-6. doi: 10.1208/s12248-009-9144-x.
4. Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10-11):1015-51.
5. Lennernäs H, Crison J, Amidon G. Permeability and clearance views of drug absorption: A commentary. J Pharmacokinet Pharmacodyn. 1995;23(3):333-7. doi: 10.1007/bf02354289.
6. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res. 1991;8(8):979-88. doi: 10.1023/a:1015892621261.
7. Lennernäs H. Human intestinal permeability. J Pharm Sci. 1998;87(4):403-10.
8. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3(6):631-43. doi: 10.1021/mp0600182.
9. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacother J Hum Pharmacol Drug Ther. 1993;13(6P2):116S-28S. doi: 10.1002/j.1875-9114.1993.tb02780.x.
10. Hardman J, Limbird LE. Goodman & Gilman's: The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
11. Benet L, Broccatelli F, Oprea T. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-47. doi: 10.1208/s12248-011-9290-9.
12. Amidon KS, Langguth P, Lennernas H, Yu L, Amidon GL. Bioequivalence of oral products and the biopharmaceutics classification system: Science, regulation, and public policy. Clin Pharmacol Ther. 2011;90(3):467-70.
13. Dahan A, Lennernäs H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 2012;9(6):1847-51. doi: 10.1021/mp300140h.
14. CDER/FDA. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical slassification system. Center for Drug Evaluation and Research; 2000.
15. Miller JM, Beig A, Carr RA, Spence JK, Dahan A. A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm. 2012;9(7):2009-16. doi: 10.1021/mp300104s.
16. Miller JM, Beig A, Carr RA, Webster GK, Dahan A. The solubility- permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations. Mol Pharm. 2012;9(3):581-90. doi: 10.1021/mp200460u.
17. Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8(5):1848-56. doi: 10.1021/mp200181v.
18. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release. 2009;137(1):31-7. doi: 10.1016/j.jconrel.2009.02.018.
19. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm. 2010;7(4):1223-34. doi: 10.1021/mp100050d.
20. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99(6):2739-49. doi: 10.1002/jps.22033.
21. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem. 2001;44(6):923-30. doi: 10.1021/jm001020e.
22. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-gp: The role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 2009;6(1):19-28. doi: 10.1021/mp800088f.
23. Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein. Pharm Res. 2009;26(4):883-92. doi: 10.1007/s11095-008-9789-7.
24. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernäs H, et al. High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Mol Pharm. 2010;7(5):1827-34. doi: 10.1021/mp100175a.
25. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7(5):1388-405. doi: 10.1021/mp100149j.
26. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009.
27. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos. 2009;37(10):2028-36. doi: 10.1124/dmd.109.028282.
28. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm. 2010;386(1-2):216-20. doi: 10.1016/j.ijpharm.2009.11.021.
29. Winne D. Shift of pH-absorption curves. J Pharmacokinet Biopharm. 1977;5(1):53-94.
30. Wagner JG, Sedman AJ. Quantitaton of rate of gastrointestinal and buccal absorption of acidic and basic drugs based on extraction theory. J Pharmacokinet Pharmacodyn. 1973;1(1):23-50.
31. Teksin ZS, Hom K, Balakrishnan A, Polli JE. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. J Control Release. 2006;116(1):50-7. doi: 10.1016/j.jconrel.2006.08.020.
32. Vree T, Muskens A, van Rossum J. Some physico-chemical properties of amphetamine and related drugs. J Pharm Pharmacol. 1969;21(11):774-5.
33. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests. Mol Pharm. 2006;3(6):686-94.
34. Polli J, Abrahamsson B, Yu L, Amidon G, Baldoni J, Cook J, et al. Summary workshop report: Bioequivalence, biopharmaceutics classification system, and beyond. AAPS J. 2008;10(2):373-9. doi: 10.1208/s12248-008-9040-9.
35. Jobin G, Cortot A, Godbillon J, Duval M, Schoeller J, Hirtz J, et al. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol. 1985;19 Suppl 2:97S-105S.
36. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. Site of drug absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci. 2006;29(3-4):240-50.
37. Dahan A, West BT, Amidon GL. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci. 2009;36(2-3):320-9. doi: 10.1016/j.ejps.2008.10.013.
38. Li LY, Amidon GL, Kim JS, Heimbach T, Kesisoglou F, Topliss JT, et al. Intestinal metabolism promotes regional differences in apical uptake of indinavir: Coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther. 2002;301(2):586-93. doi: 10.1124/jpet.301.2.586.
39. Lindahl A, Sjoberg A, Bredberg U, Toreson H, Ungell A, Lennernas H. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharm. 2004;1(5):347-56.
40. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci. 1998;87(3):360-6.
41. Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res. 1997;14(9):1210-5. doi: 10.1023/a:1012111008617.
42. Pade V, Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci. 1998;87(12):1604-7. doi: 10.1021/js980111k.
43. Palamanda J, Mei H, Morrison R, McLeod R, McCormick K, Corboz M, et al. Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. Drug Metab Lett. 2010;4(2):56-61.
44. Chen M-L, Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol Pharm. 2009;6(1):74-81. doi: 10.1021/mp8001864.